Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Jury Orders $78.4M Judgment in Drug-Pricing Trial

By Pharmaceutical Processing | February 25, 2009

By BOB JOHNSON Associated Press Writer MONTGOMERY, Alabama (AP) — Jurors ordered the German-based pharmaceutical company Sandoz Inc. on Tuesday to pay Alabama $78.4 million for causing government insurance program to pay too much for prescription drugs from 1991 to 2005. The jury ordered Sandoz, a subsidiary of Novartis AG, to pay $28.4 million to compensate the government for its losses and another $50 million in punitive damages. Jurors took about four hours over two days to return a verdict. “We had a very strong case and we are satisfied,” said attorney Jere Beasley, who represented the state in a trial lasting little more than two weeks. Sandoz attorney Tavor Novak said the company would appeal. Sandoz, which is based in Holzkirchen, Germany and has U.S. headquarters in Princeton, New Jersey, is one of more than 70 prescription drug makers sued by Alabama Attorney General Troy King in 2005 over drug prices dating to 1991. This is the third time a jury in Alabama has ruled against pharmaceutical companies in lawsuits brought by King. A year ago, an Alabama jury ordered the U.S. subsidiary of U.K. drug maker AstraZeneca to pay the state $215 million — $40 million in compensatory damages and $175 million in punitive damages. But Circuit Judge Charles Price reduced the combined amount to $160 million. In July, another Montgomery County jury found GlaxoSmithKline liable for nearly $81 million in compensatory damages and Novartis liable for about $33 million in similar damages. No punitive damages were awarded. “This sends a message that if you come into this state and steal from the neediest among us you are going to expect you are going to be held accountable. It doesn’t matter how big you are,” King said after being told of the verdict. AstraZeneca, GlaxoSmithKline and Novartis have appealed their cases to the Alabama Supreme Court. The state has settled 10 of the lawsuits for nearly $35 million. The state had asked for $28.4 million in compensatory damages, but Beasley had asked jurors to return up to five times that amount in punitive damages. In closing arguments Monday, Beasley told jurors that Sandoz was arrogant in the way it reported drug prices and noted a company memo had said: “Go forward and take the position of a Roman legion, be greedy and take no prisoners.” Novak told jurors, however, that the company reported accurate prices and Sandoz saved the Alabama agency millions by providing less expensive generic drugs. Novak said the memo was taken out of context and the reference to the Roman legion was a metaphor to inspire workers. Novak also told jurors that state officials did not understand the pricing system. The verdict is the second time this month that a jury has ruled against a pharmaceutical company being sued by a state for allegedly inflating prescription drug prices. Last week a jury in Madison, Wisconsin ruled that Parmacia Inc., a subsidiary of Pfizer Inc., had violated the state’s insurance fraud law more than 1.4 million times. The company was charged with knowingly inflating wholesale prices to obtain larger payments from the government, private insurers and consumers. The jury ordered the company to pay $9 million in damages.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE